Nkarta, Inc. NKTX
We take great care to ensure that the data presented and summarized in this overview for Nkarta, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NKTX
View all-
Ra Capital Management, L.P. Boston, MA10.8MShares$27.9 Million0.68% of portfolio
-
Commodore Capital LP New York, NY4.66MShares$12 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.06MShares$10.5 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.03MShares$10.4 Million0.97% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.77MShares$9.72 Million9.87% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.6MShares$9.29 Million0.03% of portfolio
-
Nea Management Company, LLC Timonium, MD3.57MShares$9.21 Million1.23% of portfolio
-
Sr One Capital Management, LP3.33MShares$8.6 Million5.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.14MShares$8.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.01MShares$7.77 Million0.0% of portfolio
Latest Institutional Activity in NKTX
Top Purchases
Top Sells
About NKTX
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Transactions at NKTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2024
|
David Shook |
SELL
Grant, award, or other acquisition
|
Direct |
1,352
-0.97%
|
$6,760
$5.11 P/Share
|
|
Jul 16
2024
|
Alicia J. Hager Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,396
-3.17%
|
$27,168
$8.0 P/Share
|
|
Jul 15
2024
|
David Shook |
BUY
Grant, award, or other acquisition
|
Direct |
23,421
+14.34%
|
-
|
|
Jun 18
2024
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
456
-0.3%
|
$2,280
$5.6 P/Share
|
|
Jun 18
2024
|
Ralph Brandenberger Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
229
-0.29%
|
$1,145
$5.6 P/Share
|
|
Jun 18
2024
|
Alicia J. Hager Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
727
-0.67%
|
$3,635
$5.6 P/Share
|
|
Jun 18
2024
|
David Shook |
SELL
Open market or private sale
|
Direct |
456
-0.39%
|
$2,280
$5.6 P/Share
|
|
Jun 18
2024
|
Paul J Hastings Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,770
-0.73%
|
$8,850
$5.6 P/Share
|
|
Mar 27
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+22.99%
|
$30,000,000
$10.0 P/Share
|
|
Mar 27
2024
|
Simeon George |
BUY
Open market or private purchase
|
Indirect |
2,000,000
+50.0%
|
$20,000,000
$10.0 P/Share
|
|
Mar 04
2024
|
Paul J Hastings Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
137,642
-36.4%
|
$1,789,346
$13.33 P/Share
|
|
Mar 01
2024
|
Paul J Hastings Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,358
-3.16%
|
$160,654
$13.0 P/Share
|
|
Mar 01
2024
|
Ralph Brandenberger Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
8,367
-9.47%
|
$100,404
$12.51 P/Share
|
|
Mar 01
2024
|
Ralph Brandenberger Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,763
+3.75%
|
$20,289
$3.89 P/Share
|
|
Feb 12
2024
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,143
-2.7%
|
$49,716
$12.0 P/Share
|
|
Jan 16
2024
|
David Shook |
SELL
Open market or private sale
|
Direct |
3,552
-3.0%
|
$28,416
$8.74 P/Share
|
|
Jan 16
2024
|
Paul J Hastings Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,697
-2.42%
|
$77,576
$8.74 P/Share
|
|
Jan 16
2024
|
Ralph Brandenberger Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,512
-2.99%
|
$20,096
$8.74 P/Share
|
|
Jan 16
2024
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,560
-2.88%
|
$36,480
$8.74 P/Share
|
|
Jan 16
2024
|
Alicia J. Hager Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,554
-4.05%
|
$36,432
$8.74 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 5M shares |
|---|---|
| Grant, award, or other acquisition | 388K shares |
| Exercise of conversion of derivative security | 6.76K shares |
| Sale (or disposition) back to the issuer | 150K shares |
|---|---|
| Open market or private sale | 44.4K shares |
| Grant, award, or other acquisition | 1.35K shares |